June 26, 2026 11:57 AM GMT Acadia Pharmaceuticals Inc | North America DAYBUE (trofinetide) Receives Positive CHMP Opinion: EU Approval Pending CHMP recommends EU approval of DAYBUE for Rett syndrome neurobehavioral symptoms, positioning Acadia to expand beyond the U.S. market. Approval would establish first-in-class status in EU, reinforcing commercial durability and rare disease franchise value. Key Takeaways CHMP issued a positive opinion following re-examination for DAYBUE in adults and children ≥5 years ...